Balchem/$BCPC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Balchem
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Ticker
$BCPC
Sector
Primary listing
Employees
1,364
Headquarters
Website
Balchem Metrics
BasicAdvanced
$4.6B
32.65
$4.36
0.92
$0.87
0.61%
Price and volume
Market cap
$4.6B
Beta
0.92
52-week high
$182.46
52-week low
$139.17
Average daily volume
156K
Dividend rate
$0.87
Financial strength
Current ratio
2.641
Quick ratio
1.458
Long term debt to equity
14.985
Total debt to equity
14.985
Dividend payout ratio (TTM)
19.81%
Interest coverage (TTM)
15.85%
Profitability
EBITDA (TTM)
243.333
Gross margin (TTM)
35.80%
Net profit margin (TTM)
14.48%
Operating margin (TTM)
20.22%
Effective tax rate (TTM)
22.97%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
7.68%
Return on equity (TTM)
11.99%
Valuation
Price to earnings (TTM)
32.649
Price to revenue (TTM)
4.676
Price to book
3.64
Price to tangible book (TTM)
16.52
Price to free cash flow (TTM)
29.949
Free cash flow yield (TTM)
3.34%
Free cash flow per share (TTM)
4.752
Dividend yield (TTM)
0.61%
Forward dividend yield
0.61%
Growth
Revenue change (TTM)
5.74%
Earnings per share change (TTM)
21.42%
3-year revenue growth (CAGR)
4.00%
10-year revenue growth (CAGR)
5.04%
3-year earnings per share growth (CAGR)
9.30%
10-year earnings per share growth (CAGR)
7.90%
3-year dividend per share growth (CAGR)
10.78%
10-year dividend per share growth (CAGR)
11.23%
What the Analysts think about Balchem
Analyst ratings (Buy, Hold, Sell) for Balchem stock.
Bulls say / Bears say
Balchem delivered record net sales of $255.5 million in Q2 2025, a 9.1% increase over the prior year quarter, driven by growth across all three reporting segments. (GlobeNewswire)
The company achieved a record adjusted EBITDA of $69.2 million in Q2 2025, up 11.2% year-over-year, reflecting strong operating leverage and effective cost management across its specialties. (GlobeNewswire)
Balchem announced a $36 million investment to build a state-of-the-art micro-encapsulation facility in Orange County, NY, which is expected to more than double its production capacity and support future growth in its high-margin nutrition business. (GlobeNewswire)
Raw materials prices in the chemicals sector have risen more than 15%, a level of cost inflation that is likely to pressure Balchem’s manufacturing margins and squeeze profitability. (Reuters)
The German chemicals lobby has trimmed its annual sales forecast by 14% due to high energy costs and weakening production volumes, signaling demand headwinds that could dampen Balchem’s specialty ingredient markets. (Reuters)
Balchem’s operating expenses rose by $4.5 million in Q2 2025, increasing year-over-year by over 12%, which may constrain its free cash flow and earnings leverage. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Balchem Financial Performance
Revenues and expenses
Balchem Earnings Performance
Company profitability
Balchem News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Balchem stock?
Balchem (BCPC) has a market cap of $4.6B as of October 15, 2025.
What is the P/E ratio for Balchem stock?
The price to earnings (P/E) ratio for Balchem (BCPC) stock is 32.65 as of October 15, 2025.
Does Balchem stock pay dividends?
Yes, the Balchem (BCPC) stock pays dividends to shareholders. As of October 15, 2025, the dividend rate is $0.87 and the yield is 0.61%. Balchem has a payout ratio of 19.81% on a trailing twelve-month basis.
When is the next Balchem dividend payment date?
The next Balchem (BCPC) dividend payment date is unconfirmed.
What is the beta indicator for Balchem?
Balchem (BCPC) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.